Sugi Predict

Sugi Predict / Compounds / Ammonia Solution, Strong

Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL1483368

CCCCCCCCCCC(CS(=O)(=O)O)OCCC.N

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.41
▸ DNM1 Q05193 1/20 0.37
▸ LPAR1 Q92633 2/20 0.36
▸ LPAR3 Q9UBY5 2/20 0.36
▸ SMPD1 P17405 3/20 0.35
▸ CA1 P00915 5/20 0.34
▸ CA2 P00918 5/20 0.34
▸ CA9 Q16790 5/20 0.34
▸ FDPS P14324 3/20 0.34
▸ GPR84 Q9NQS5 2/20 0.34
▸ CA12 O43570 1/20 0.34
▸ CA3 P07451 1/20 0.34
▸ CA4 P22748 1/20 0.34
▸ CA6 P23280 1/20 0.34
▸ CA5A P35218 1/20 0.34
▸ CA7 P43166 1/20 0.34
▸ CA14 Q9ULX7 1/20 0.34
▸ CA5B Q9Y2D0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11784357 0.97 TP53 (0.41) TP53DNM1LPAR1LPAR3SMPD1
SCHEMBL11581244 0.90 TP53 (0.41) TP53DNM1LPAR1LPAR3SMPD1
Ammonia Solution, Strong SCHEMBL1483369 0.85 S1PR2 (0.40) TP53DNM1LPAR1LPAR3SMPD1
Ammonia Solution, Strong SCHEMBL8708050 0.85 EPHX2 (0.40) TP53DNM1LPAR1LPAR3SMPD1
SCHEMBL1483864 0.85 TP53 (0.46) TP53SMPD1CA1CA2FDPS
SCHEMBL11796161 0.85 TP53 (0.46) TP53SMPD1CA1CA2FDPS
SCHEMBL996196 0.81 DNM1 (0.48) DNM1LPAR1LPAR3CA1CA2
SCHEMBL995955 0.81 DNM1 (0.48) DNM1LPAR1LPAR3CA1CA2
SCHEMBL995593 0.81 DNM1 (0.48) DNM1LPAR1LPAR3CA1CA2
SCHEMBL999453 0.81 DNM1 (0.48) DNM1LPAR1LPAR3CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11110175-B2 Compositions with permeation enhancers for drug delivery CHILDREN'S MEDICAL CENTER CORPORATION (US) 2021-09-07 — — US disclosed
US-20200138710-A1 COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY CHILDREN'S MEDICAL CENTER CORPORATION (US) 2020-05-07 — — US disclosed
US-8822410-B2 Tympanic membrane permeating ear drops and uses thereof CHILDREN'S MEDICAL CENTER CORPORATION (US) 2014-09-02 — — US disclosed
US-20110166060-A1 TYMPANIC MEMBRANE PERMEATING EAR DROPS AND USES THEREOF MASSACHUSETTES INSTITUTE OF TECHNOLOGY (US) 2011-07-07 — — US disclosed
EP-2337544-A2 USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE Living Proof, Inc. (US) 2011-06-29 — — EP disclosed
US-20110082118-A1 Onychomycosis Treatment Delivery System PRUGEN IP HOLDINGS, INC 2011-04-07 — — US disclosed
US-20110076261-A1 Antifungal Drug Delivery System PRUGEN IP HOLDINGS, INC 2011-03-31 — — US disclosed
WO-2009142719-A2 TYMPANIC MEMBRANE PERMEATING EAR DROPS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2009-11-26 — — WO disclosed
US-20090068255-A1 USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE LIVING PROOF, INC. 2009-03-12 — — US disclosed
US-20080317737-A1 Drug combination for the treatment of skin disorders PRUGEN, INC. 2008-12-25 — — US disclosed
US-4842850-A SHAMPOO THE PROCTER & GAMBLE COMPANY (US) 1989-06-27 — — US disclosed
EP-0313307-A1 Hair care compositions THE PROCTER & GAMBLE COMPANY (US) 1989-04-26 — — EP disclosed
US-4788006-A Shampoo compositions containing nonvolatile silicone and xanthan gum THE PROCTER & GAMBLE COMPANY (US) 1988-11-29 — — US disclosed
EP-0240350-A2 Hair care compositions THE PROCTER & GAMBLE COMPANY (US) 1987-10-07 — — EP disclosed
US-4292035-A COMPLEX OF SMECTITE CLAYS, AMINES, AND ORGANIC SULFONIUM, PHOSPHONIUM, OR QUATERNARY AMMONIUM COMPOUNDS, WITH AN ANIONIC SURFACTANT THE PROCTER & GAMBLE COMPANY (US) 1981-09-29 — — US disclosed
US-4174291-A DETERGENTS THE PROCTER & GAMBLE COMPANY (US) 1979-11-13 — — US disclosed
US-4101455-A Low phosphate content glassy phosphate detergent compositions having optimum detergency THE PROCTER & GAMBLE COMPANY (US) 1978-07-18 — — US disclosed
US-4062647-A Clay-containing fabric softening detergent compositions THE PROCTER & GAMBLE COMPANY (US) 1977-12-13 — — US disclosed
US-4051046-A ANTISTATIC AGENTS, SOFTENERS, WRINKLE RESISTANCE THE PROCTER & GAMBLE COMPANY (US) 1977-09-27 — — US disclosed
US-4000080-A ETHYLENE OXIDE CONDENSATION PRODUCT WITH MALEIC ANHYDRIDE-VINYL METHYL ETHER COPOLYMER THE PROCTER & GAMBLE COMPANY (US) 1976-12-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090068255-A1 USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE MMP1, MMP9, MMP17 TP53 465/4885DNM1 1677/4885LPAR1 1770/4885
US-11110175-B2 Compositions with permeation enhancers for drug delivery ABCB11, MMP1, SLC47A1 TP53 3120/4885DNM1 1235/4885LPAR1 2379/4885
US-20200138710-A1 COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY ABCB11, CFTR, MMP1 TP53 3276/4885DNM1 1041/4885LPAR1 2448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.